<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02107209</url>
  </required_header>
  <id_info>
    <org_study_id>MD68</org_study_id>
    <nct_id>NCT02107209</nct_id>
  </id_info>
  <brief_title>Low Cost Biological Lung Volume Reduction Therapy for Advanced Emphysema</brief_title>
  <acronym>BLVR</acronym>
  <official_title>Evaluation of Bronchoscopic Biological Lung Volume Reduction Therapy in Pulmonary Emphysema Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical utility of bronchoscopic methods for achieving lung volume reduction has been
      evaluated in patients with advanced emphysema because these procedures are uniformly safer
      than surgical volume reduction. These include one-way valves, or bronchial occlusive devices
      to collapse emphysematous regions of lung and bronchial fenestration with bypass stents to
      improve expiratory flow, wire coils implants that compress the airway and thermal vapor
      ablation that causes an acute injury with subsequent fibrosis and reductions in volume.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Biologic lung volume reduction (BioLVR): it is a novel endobronchial approach, which uses a
      Biological agents aiming to reduce lung volume by blocking off the most emphysematous areas
      with a rapidly polymerizing sealant. The mechanism of action involves resorption atelectasis
      from airway occlusion, subsequent airspace inflammation, and then remodeling. This remodeling
      will lead to scarring that induces contraction of lung parenchyma and functional volume
      reduction can be expected within 6-8 weeks. Biological lung volume reduction occurs
      independent of the presence or absence of collateral ventilation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-procedure lung volume reduction</measure>
    <time_frame>12 week</time_frame>
    <description>Change from the baseline high-resolution computed tomography (HRCT) volumetry Change from the baseline Residual Volume/Total Lung Capacity from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-procedure Improvement in dyspnea and exercise capacity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes from the baseline post-bronchodilator forced expiratory volume at one second (FEV1) and forced vital capacity (FVC), diffusing capacity of lung for carbon monoxide (DLCO), six-minute walk distance (6MWD),modified medical research council (MMRC) dyspnea score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Pulmonary Emphysema</condition>
  <arm_group>
    <arm_group_label>Bronchoscopic Lung volume reduction using Autologous blood.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of 30 ml autologous blood plus 3ml calcium chloride plus 3 ml tranexamic acid per segment via fiber-optic bronchoscope</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bronchoscopic Lung volume reduction using Fibrin glue</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>injection of 30 ml locally prepared fibrin glue per segment via triple lumen balloon catheter passing through fiberoptic bronchoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bronchoscopic Lung volume reduction</intervention_name>
    <description>Fiberoptic bronchoscopy is used to inject the biological agents into the targeted lung segment</description>
    <arm_group_label>Bronchoscopic Lung volume reduction using Autologous blood.</arm_group_label>
    <arm_group_label>Bronchoscopic Lung volume reduction using Fibrin glue</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Emphysema determined by HRCT of the chest with:

               -  .Persistent symptoms (i.e. a baseline Modified Medical Research Council dyspnea
                  (MRC) score of &gt;2 despite medical therapy).

               -  FEV1 /FVC &lt; 70% and FEV1 20%-50 % (Sever and very sever airflow limitation
                  according to GOLD 2013).

               -  Hyperinflation (total lung capacity (TLC) &gt; 110% pred and residual volume/total
                  lung capacity (RV/TLC) &gt; 120% pred.

          2. Patients not candidate for or had refused lung volume reduction surgery.

          3. Age &gt; 40 yrs.

        Exclusion Criteria:

          1. Airflow limitation with FEV1 &lt; 20%.

          2. DLCO &lt; 20%.

          3. Current smoker.

          4. Patients not candidate for FOB.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmad Saad El-Morsi, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Chest Medicine Department, Faculty of Medicine, Mansoura University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chest Medicine Department, Faculty Of Medicine, Mansoura University</name>
      <address>
        <city>Mansoura</city>
        <state>Al-dakahliya</state>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2014</study_first_submitted>
  <study_first_submitted_qc>April 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2014</study_first_posted>
  <last_update_submitted>November 10, 2015</last_update_submitted>
  <last_update_submitted_qc>November 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Mostafa Bakeer</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

